Management holds a KOL conference call with Drs. Alcalay and Lansbury to discuss the P1b Parkinson’s Disease data for GT-02287 on January 6 at 10 am. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Gain Therapeutics price target raised to $10 from $6 at Roth Capital
- Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
- Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
- Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
- Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint